ATLAS: a phase 2, open-label study of rucaparib in patients with locally advanced (unresectable) or metastatic urothelial carcinoma - Feyerabend, S.; Boegemann, M.; Goebell, Peter; Stoeckle, M.; Nepert, D.; Wride, K.; Thomas, D.; Loehr, A.; Simmons, A.; Grivas, P.; Chowdhury, S. (2018)
EVALuna2:35895